Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 4, 2007 - Issue 6
Submit an article Journal homepage
343
Views
30
CrossRef citations to date
0
Altmetric
Review

Design of nanoparticle-based dry powder pulmonary vaccines

Brian Pulliam Graduate Program in Biophysics, Harvard University Faculty of Arts and Sciences, 40 Oxford Street, ESL 406, Cambridge, MA 02138, USA
,
Jean C Sung Graduate Program in Bioengineering, Harvard School of Engineering and Applied Sciences, 40 Oxford Street, ESL 406, Cambridge, MA 02138, USA
&
David A Edwards Gordon McKay Professor of the Practice of Biomedical Engineering, Harvard School of Engineering and Applied Sciences, 322 Pierce Hall, 29 Oxford Street, Cambridge, MA 02138, USA +1 617 495 1328; +1 617 495 9837; [email protected]
Pages 651-663 | Published online: 31 Oct 2007

Bibliography

  • VARMUS H, KLAUSNER R, ZERHOUNI E et al.; PUBLIC HEALTH: Enhanced: grand challenges in global health. Science (2003) 302(5644):398-399.
  • GIUDICE EL, CAMPBELL JD: Needle-free vaccine delivery. Adv. Drug Deliv. Rev. (2006) 58(1):68-89.
  • STEVCEVA L, ABIMIKU AG, FRANCHINI G: Targeting the mucosa: genetically engineered vaccines and mucosal immune responses. Gene Immun. (2000) 1(5):308.
  • BOUVET J-P, DECROIX N, PAMONSINLAPATHAM P: Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol. (2002) 23(4):209-213.
  • OGRA PL, FADEN H, WELLIVER RC: Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. (2001) 14(2):430-445.
  • MCNEELA EA, MILLS KHG: Manipulating the immune system: humoral versus cell-mediated immunity. Adv. Drug Deliv. Rev. (2001) 51(1-3):43-54.
  • MOYLE PM, MCGEARY RP, BLANCHFIELD JT, TOTH I: Mucosal immunisation: adjuvants and delivery systems. Curr. Drug Deliv. (2004) 1(4):385-396.
  • BIVAS-BENITA M, OTTENHOFF THM, JUNGINGER HE, BORCHARD G: Pulmonary DNA vaccination: concepts, possibilities and perspectives. J. Control. Rel. (2005) 107(1):1-29.
  • VALENTE A, LANGER R, STONE H, EDWARDS D: Recent advances in the development of an inhaled insulin product. Biodrugs (2003) 17(1):9-17.
  • BOSQUILLON C, PREAT V, VANBEVER R: Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Rel. (2004) 96(2):233-244.
  • HUANG J, GARMISE RJ, CROWDER TM et al.: A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine (2004) 23(6):794-801.
  • LICALSI C, CHRISTENSEN T, BENNETT JV, PHILLIPS E, WITHAM C: Dry powder inhalation as a potential delivery method for vaccines. Vaccine (1999) 17(13-14):1796-1803.
  • SMITH DJ, BOT S, DELLAMARY L, BOT A: Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine (2003) 21(21-22):2805-2812.
  • LICALSI C, MANIACI MJ, CHRISTENSEN T et al.: A powder formulation of measles vaccine for aerosol delivery. Vaccine (2001) 19(17-19):2629-2636.
  • SCHIJNS VEJC: Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine (2003) 21(9-10):829-831.
  • ALLEN TM, CULLIS PR: Drug delivery systems: entering the mainstream. Science (2004) 303(5665):1818-1822.
  • O'HAGAN DT: Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. (1998) 34(2-3):305-320.
  • FESSI H, PUISIEUX F, DEVISSAGUET JP, AMMOURY N, BENITA S: Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. (1989) 55(R1-R4).
  • KREUTER J: Nanoparticles. In: Encyclopedia of Pharmaceutical Technology. Swarbrick J & Boylan JC (Eds), M Dekker, New York (1994):165-190.
  • ASTM COMMITTEE E56: ASTM Standards: E2456 Standard Terminology Relating to Nanotechnology, (E2456) ASTM International (2006).
  • NAIR L, LAURENCIN C: Polymers as biomaterials for tissue engineering and controlled drug delivery. In: Tissue Engineering I (2006):47-90.
  • LANGER R: New methods of drug delivery. Science (1990) 249(4976):1527-1533.
  • KREUTER J: Nanoparticles – a historical perspective. Int. J. Pharm. (2007) 331(1):1-10.
  • ALPAR HO, SOMAVARAPU S, ATUAH KN, BRAMWELL VW: Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. (2005) 57(3):411-430.
  • DONG Y, RUAN Y, WANG H, ZHAO Y, BI D: Studies on glass transition temperature of chitosan with four techniques. J. Appl. Polymer Sci. (2004) 93:1553-1558.
  • KENLEY RA, LEE MO, MAHONEY TR, SANDERS LM: Poly(lactide-co-glycolide) decomposition kinetics in vivo and in vitro. Macromolecules (1987) 20(10):2398-2403.
  • ZWEERS MLT, ENGBERS GHM, GRIJPMA DW, FEIJEN J: In vitro degradation of nanoparticles prepared from polymers based on DL-lactide, glycolide and poly(ethylene oxide). J. Control. Rel. (2004) 100(3):347-356.
  • CLELAND J: Single-administration vaccines: controlled-release technology to mimic repeated immunizations. TIBTECH (1999) 17:25-29.
  • HAUSBERGER AG, DELUCA PP: Characterization of biodegradable poly(-lactide-co-glycolide) polymers and microspheres. J. Pharmaceut. Biomed. Anal. (1995) 13(6):747-760.
  • SCHENDERLEIN S, LUCK M, MULLER BW: Partial solubility parameters of poly(D,L-lactide-co-glycolide). Int. J. Pharm. (2004) 286(1-2):19-26.
  • LAVIK E, LANGER R: Tissue engineering: current state and perspectives. Appl. Microbiol. Biotechnol. (2004) 65(1):1-8.
  • JAIN RA: The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials (2000) 21(23):2475-2490.
  • LAMPRECHT A, UBRICH N, HOMBREIRO PEREZ M et al.: Biodegradable monodispersed nanoparticles prepared by pressure homogenization–emulsification. Int. J. Pharm. (1999) 184(1):97-105.
  • NIWA T, TAKEUCHI H, HINO T, KUNOU N, KAWASHIMA Y: Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Rel. (1993) 25(1-2):89-98.
  • GUPTA PN, MAHOR S, RAWAT A et al.: Lectin anchored stabilized biodegradable nanoparticles for oral immunization. 1. Development and in vitro evaluation. Int. J. Pharm. (2006) 318(1-2):163-173.
  • TAMBER H, JOHANSEN P, MERKLE HP, GANDER B: Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. (2005) 57(3):357-376.
  • FALK R, PHILIPSON K, SVARTENGREN M et al.: Assessment of long-term bronchiolar clearance of particles from measurements of lung retention and theoretical estimates of regional deposition. Exp. Lung Res. (1999) 25(6):495-516.
  • CLARKE SW, PAVIA D (Eds): Aerosols and the Lung: Clinical and Experimental Aspects. Butterworths, London, Boston (1984):275.
  • PHILIPSON K, FALK R, SVARTENGREN M et al.: Does lung retention of inhaled particles depend on their geometric diameter? Exp. Lung Res. (2000) 26(6):437-455.
  • EDWARDS DA, BEN-JEBRIA A, LANGER R: Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. (1998) 85(2):379-385.
  • VANBEVER R, MINTZES JD, WANG J et al.: Formulation and physical characterization of large porous particles for inhalation. Pharmaceut. Res. (1999) 16(11):1735-1742.
  • BAILEY MR: The new ICRP model for the respiratory tract. Radiat. Prot. Dosimetry (1994) 53(1-4):107-114.
  • BAILEY M, ANSOBORLO E, GUILMETTE R, PAQUET F: Practical application of the ICRP human respiratory tract model. Radiat. Prot. Dosimetry (2003) 105(1-4):71-76.
  • HINDS WC: Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles. (Ed.), Wiley, New York (1999) XX:483.
  • GERRITY TR, LEE PS, HASS FJ et al.: Calculated deposition of inhaled particles in the airway generations of normal subjects. J. Appl. Physiol. (1979) 47(4):867-873.
  • SMITH IJ, PARRY-BILLINGS M: The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. (2003) 16(2):79-95.
  • TELKO M, HICKEY A: Dry powder inhaler formulation. Respir. Care (2005) 50(9):1209-1227.
  • EDWARDS DA, HANES J, CAPONETTI G et al.: Large porous particles for pulmonary drug delivery. Science (1997) 276(5320):1868-1872.
  • TSAPIS N, BENNETT D, JACKSON B, WEITZ DA, EDWARDS DA: Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. USA (2002) 99(19):12001-12005.
  • SHAM JO-H, ZHANG Y, FINLAY WH, ROA WH, LOBENBERG R: Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm. (2004) 269(2):457-467.
  • MASTERS K: Spray Drying Handbook. Longman Scientific & Technical; John Wiley, Essex England, New York (1991):XIV, 725.
  • HADINOTO K, PHANAPAVUDHIKUL P, KEWU Z, TAN RBH: Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind. Eng. Chem. Res. (2006) 45(10):3697-3706.
  • HADINOTO K, PHANAPAVUDHIKUL P, KEWU Z, TAN RBH: Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int. J. Pharm. (2007) 333(1-2):187-198.
  • WONG Y-L, SAMPSON S, GERMISHUIZEN WA et al.: Drying a tuberculosis vaccine without freezing. Proc. Natl. Acad. Sci. USA (2007) 104(8):2591-2595.
  • RABBANI NR, SEVILLE PC: The influence of formulation components on the aerosolisation properties of spray-dried powders. J. Control. Rel. (2005) 110(1):130-140.
  • LIPPMANN M: Effects of fiber characteristics on lung deposition, retention, and disease. Environ. Health Perspect. (1990) 88:311-317.
  • MURAKAMI H, KOBAYASHI M, TAKEUCHI H, KAWASHIMA Y: Preparation of poly(-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int. J. Pharm. (1999) 187(2):143-152.
  • JOHNSON BK, PRUD'HOMME RK: Mechanism for rapid self-assembly of block copolymer nanoparticles. Phys. Rev. Lett. (2003) 91(11):118302.
  • AMIDI M, ROMEIJN SG, VERHOEF JC et al.: N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine (2007) 25(1):144-153.
  • GANACHAUD F, KATZ JL: Nanoparticles and nanocapsules created using the ouzo effect: spontaneous emulsification as an alternative to ultrasonic and high-shear devices. ChemPhysChem (2005) 6(2):209-216.
  • WENDORF J, SINGH M, CHESKO J et al.: A practical approach to the use of nanoparticles for vaccine delivery. J. Pharmaceut. Sci. (2006) 95(12):2738-2750.
  • KYD JM, FOXWELL AR, CRIPPS AW: Mucosal immunity in the lung and upper airway. Vaccine (2001) 19(17-19):2527-2533.
  • SINGH M, O'HAGAN D: Advances in vaccine adjuvants. Nat. Biotech. (1999) 17(11):1075-1081.
  • ULANOVA M, TARKOWSKI A, HAHN-ZORIC M, HANSON LA: The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. (2001) 69(2):1151-1159.
  • SINGH M, O'HAGAN DT: Recent advances in vaccine adjuvants. Pharmaceut. Res. (2002) 19(6):715-728.
  • RUSSELL-JONES GJ: Oral vaccine delivery. J. Control. Rel. (2000) 65(1-2):49-54.
  • LITWIN SD, SINGER JM: The adjuvant action of latex particulate carriers. J. Immunol. (1965) 95(6):1147-1152.
  • BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245.
  • ELAMANCHILI P, DIWAN M, CAO M, SAMUEL J: Characterization of poly(-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine (2004) 22(19):2406-2412.
  • LUTSIAK MEC, ROBINSON DR, COESTER C, KWON GS, SAMUEL J: Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages. Pharm. Res. (2002) 19(10):1480-1487.
  • ELAMANCHILI P, DIWAN M, CAO M, SAMUEL J: Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine (2004) 22:2406-2412.
  • DESAI MP, LABHASETWAR V, WALTER E, LEVY RJ, AMIDON GL: The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharmaceut. Res. (1997) 14(11):1568-1573.
  • ELDRIDGE J, GILLEY R, STAAS J et al.: Biodegradable microspheres: vaccine delivery system for oral immunization. Curr. Top. Microbiol. Immunol. (1989) 146:59-66.
  • MINIGO G, SCHOLZEN A, TANG CK et al.: Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine (2007) 25(7):1316-1327.
  • SAHOO SK, PANYAM J, PRABHA S, LABHASETWAR V: Residual polyvinyl alcohol associated with poly (-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J. Control. Rel. (2002) 82(1):105-114.
  • ILLUM L: Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J. Pharmaceut. Sci. (2007) 96(3):473-483.
  • JAGANATHAN KS, VYAS SP: Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine (2006) 24(19):4201-4211.
  • REDDY ST, SWARTZ MA, HUBBELL JA: Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. (2006) 27(12):573-579.
  • DIWAN M, ELAMANCHILI P, LANE H, GAINER A, SAMUEL J: Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J. Drug Target. (2004) 11(8):495-507.
  • SEMMLER-BEHNKE M, TAKENAKA S, FERTSCH S et al.: Efficient elimination of inhaled nanoparticles from the alveolar region: evidence for interstitial uptake and subsequent re-entrainment onto airways epithelium. Environ. Health Perspect. (2007) 114(5):728-733.
  • SMINIA T: A review of the mucosal immune system: development, structure, and function of the upper and lower respiratory tract. Eur. Respir. Rev. (1996) 6:136-141.
  • BIVAS-BENITA M, ROMEIJN S, JUNGINGER HE, BORCHARD G: PLGA–PEI nanoparticles for gene delivery to pulmonary epithelium. Eur. J. Pharm. Biopharm. (2004) 58(1):1-6.
  • BRZOSKA M, LANGER K, COESTER C et al.: Incorporation of biodegradable nanoparticles into human airway epithelium cells – in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary disease. Biochem. Biophys. Res. Commun. (2004) 318:562-570.
  • BIVAS-BENITA M, VAN MEIJGAARDEN KE, FRANKEN KLMC et al.: Pulmonary delivery of chitosan–DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine (2004) 22(13-14):1609-1615.
  • JANES KA, CALVO P, ALONSO MJ: Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. (2001) 47(1):83-97.
  • BANERJEE T, MITRA S, KUMAR SINGH A, KUMAR SHARMA R, MAITRA A: Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. Int. J. Pharm. (2002) 243(1-2):93-105.
  • WARTLICK H, SPANKUCH-SCHMITT B, STREBHARDT K, KREUTER J, LANGER K: Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J. Control. Rel. (2004) 96(3):483-495.
  • REIS CP, NEUFELD RJ, VILELA S, RIBEIRO AONJ, VEIGA F: Review and current status of emulsion/dispersion technology using an internal gelation process for the design of alginate particles. J. Microencapsul. (2006) 23(3):245-257.
  • HORN D, RIEGER J: Organic nanoparticles in the aqueous phase – theory, experiment, and use. Angew. Chem. Int. Ed. (2001) 40(23):4330-4361.
  • RAULA J, EERIKAINEN H, KAUPPINEN EI: Influence of the solvent composition on the aerosol synthesis of pharmaceutical polymer nanoparticles. Int. J. Pharm. (2004) 284(1-2):13-21.
  • MACHLUF M, APTE RN, REGEV O, COHEN S: Enhancing the immunogenicity of liposomal hepatitis B surface antigen (HBsAg) by controlling its delivery from polymeric microspheres. J. Pharmaceut. Sci. (2000) 89(12):1550-1557.
  • UCHIDA T, SHIOSAKI K, NAKADA Y et al.: Microencapsulation of hepatitis B core antigen for vaccine preparation. Pharmaceut. Res. (1998) 15(11):1708-1713.
  • CHONG CSW, CAO M, WONG WW et al.: Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J. Control. Rel. (2005) 102(1):85-99.
  • MEN Y, GANDER B, MERKLE HP, CORRADIN G: Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine (1996) 14(15):1442-1450.
  • CARCABOSO Ã, HERNÃNDEZ R, IGARTUA M et al.: Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration. Pharmaceut. Res. (2004) 21(1):121-126.
  • LEMOINE D, PREAT V: Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J. Control. Rel. (1998) 54(1):15-27.
  • EVANS JT, WARD JR, KERN J, JOHNSON ME: A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. Vaccine (2004) 22(15-16):1964-1972.
  • AMIDI M, PELLIKAAN HC, HIRSCHBERG H et al.: Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine (2007) 25(37-38):6818-6829.
  • RYDELL N, SJOHOLM I: Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine (2004) 22(9-10):1265-1274.
  • JOHANSEN P, ESTEVEZ F, ZURBRIGGEN R et al.: Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine (2000) 19(9-10):1047-1054.
  • MEN Y, THOMASIN C, MERKLE HP, GANDER B, CORRADIN G: A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine (1995) 13(7):683-689.
  • STURESSON C, DEGLING WIKINGSSON L: Comparison of poly(acryl starch) and poly(lactide-co-glycolide) microspheres as drug delivery system for a rotavirus vaccine. J. Control. Rel. (2000) 68(3):441-450.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.